Key result
Sotalol is an attractive option for the treatment and prevention of atrial fibrillation due to its combination of class II and class III antiarrhythmic properties.
Why the study?
Does sotalol prevent recurrences of atrial fibrillation in patients with atrial fibrillation?
Does sotalol prevent recurrences of atrial fibrillation in patients with atrial fibrillation?
Sotalol is highlighted as an attractive option for rhythm control in atrial fibrillation due to its dual class II and class III antiarrhythmic properties.
Supports sotalol consideration for AF rhythm control; leaves open need for updated head-to-head RCTs.
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in clinical practice and is a major cause of morbidity and mortality. It represents an extremely costly public health problem with a negative impact on the quality of life of patients affected. Despite many drugs that are currently available in preventing recurrences of AF after successful cardioversion to normal sinus rhythm, their efficacy remains unsatisfactory, with a great number of recurrences and several short- and long-term adverse effects. Sotalol is an antiarrhythmic drug with a combination of class II (β-adrenoceptor blocking) and class III (cardiac action potential duration prolongation) properties, making it an attractive option for the treatment and prevention of AF.
No takes yet. Share an insight, caveat, or question.
Marinelli et al. (2010) conducted a review in Atrial fibrillation. Sotalol was evaluated. Sotalol is an attractive option for the treatment and prevention of atrial fibrillation due to its combination of class II and class III antiarrhythmic properties.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: